“…Examples includes 1) monoclonal antibodies (trastuzumab and cetuximab) in human epidermal growth factor receptor 2-positive breast cancer and wild-type KRAS colorectal cancer; 2) tyrosine kinase inhibitors (TKIs) such as imatinib, gefitinib, erlotinib, and crizotinib in chronic myeloid leukemia, gastrointestinal stromal tumors, and non-small cell lung cancers; and 3) intracellular agents (vemurafenib and olaparib) in metastatic malignant melanoma and ovarian, breast, and prostate cancers. 19 As shown in other studies, DNA extracted from previously stained cytological slides can be amplified with PCR [21][22][23][24][25] or can be used for conventional comparative genomic hybridization. 26 More recently, several authors have reported successful genetic analyses with qPCR and DNA targeted sequencing of dozens of hotspot mutations of interest.…”